These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6865963)

  • 1. Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response.
    Riederer P; Reynolds GP; Jellinger K; Seemann D; Danielczyk W
    Mod Probl Pharmacopsychiatry; 1983; 19():154-61. PubMed ID: 6865963
    [No Abstract]   [Full Text] [Related]  

  • 2. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
    Reynolds GP; Riederer P
    Int Pharmacopsychiatry; 1981; 16(1):30-3. PubMed ID: 7298269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAO inhibition as antidepressive mechanism reevaluated. A controlled study with tranylcypromine isomers.
    Beckmann H; Moises HW
    Mod Probl Pharmacopsychiatry; 1983; 19():211-4. PubMed ID: 6865965
    [No Abstract]   [Full Text] [Related]  

  • 4. Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.
    Reynolds GP; Riederer P; Sandler M
    J R Soc Med; 1981 Sep; 74(9):649-52. PubMed ID: 7288807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoinduction of hypertensive reactions by tranylcypromine?
    Keck PE; Pope HG; Nierenberg AA
    J Clin Psychopharmacol; 1989 Feb; 9(1):48-51. PubMed ID: 2486182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tranylcypromine isomers in depressed outpatients: effects on depression, monoamine oxidase inhibition and tyramine pressor response.
    Van de Merwe TJ; Pare CM; Glover V; Sandler M
    Mod Probl Pharmacopsychiatry; 1983; 19():189-202. PubMed ID: 6346066
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoamine oxidase-B, monoamine oxidase-B inhibitors, and Parkinson's disease. A role for superoxide dismutase?
    Sandler M; Glover V; Clow A; Jarman J
    Adv Neurol; 1993; 60():238-41. PubMed ID: 8420141
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of tranylcypromine stereoisomers on depressive syndromes.
    Rüther E; Jungkunz G; Greil W; Zimmer R
    Mod Probl Pharmacopsychiatry; 1983; 19():203-10. PubMed ID: 6865964
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
    Narabayashi H; Yamaguchi T; Sugi K; Mitamura H; Mizuno Y; Nakashima M
    Clin Neuropharmacol; 1999; 22(6):340-6. PubMed ID: 10626094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tranylcypromine withdrawal phenomena.
    Halle MT; Dilsaver SC
    J Psychiatry Neurosci; 1993 Jan; 18(1):49-50. PubMed ID: 8461282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report.
    Clemons WE; Makela E; Young J
    Sleep Med; 2004 Sep; 5(5):509-11. PubMed ID: 15341899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tranylcypromine lowers human platelet MAO B activity but not concentration.
    Fritz RR; Malek-Ahmadi P; Rose RM; Denney RM; Abell CW
    Biol Psychiatry; 1983 Jun; 18(6):685-94. PubMed ID: 6871302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained effects of phenelzine and tranylcypromine on orthostatic challenge in antidepressant-refractory depression.
    Tulen JH; Volkers AC; van den Broek WW; Bruijn JA
    J Clin Psychopharmacol; 2006 Oct; 26(5):542-4. PubMed ID: 16974207
    [No Abstract]   [Full Text] [Related]  

  • 20. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.